Who is sponsoring NCT02138500?

NCT02138500 is sponsored by Pfizer.

What drugs are being tested in NCT02138500?

Interventions: PF-06372865, PF-06372865, PF-06372865.

What is the status of NCT02138500?

NCT02138500 is currently COMPLETED.

Last reviewed 2014-09-23 · How we verify

A Phase 1, Open-label Study To Evaluate Central Occupancy Of The Benzodiazepine Binding Site Of Gabaa Receptors By Positron Emission Tomography (Pet) With Ligand [11c]Flumazenil Following Single Dose Of Pf-06372865 In Healthy Subjects

NCT02138500 Phase 1 COMPLETED

This study will see how PF-06372865, an experimental drug distributes in the brain after one dose of PF-06372865 is administered orally to healthy volunteer subjects. The study will also evaluate the safety and tolerability of PF-06372865in these subjects and will measure the level of PF-06372865 in the blood.

Details

Lead sponsor	Pfizer
Phase	Phase 1
Status	COMPLETED
Enrolment	5
Start date	2014-05
Completion	2014-08

Conditions

Healthy

Interventions

PF-06372865
PF-06372865
PF-06372865

Primary outcomes

GABAA RO in the whole brain — Change from baseline to days 1 and 2
Average plasma concentration of PF-06372865 in post-dose PET scans after single oral doses of PF-06372865 — Change from baseline to days 1 and 2

Countries

United States